---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-037654"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:00:16.706667+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale

## Summary
- Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.
- ABVC has 45 days to submit a compliance plan; if accepted, it may have until Oct 21, 2025 to regain compliance.
- Sold 724,372 common shares to 15 non-U.S. persons for gross proceeds of ~$436,000 under Regulation S.
- Each purchaser agreed to transfer voting rights to Chairman Eugene Jiang via a Voting Rights Proxy Agreement.

## SEC filing metadata
- accession: 0001213900-25-037654
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/0001213900-25-037654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/ea0239740-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-037654
- JSON: https://secwatch.observer/filing/0001213900-25-037654.json
- Plain text: https://secwatch.observer/filing/0001213900-25-037654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.